Delayed in Biological Technology
Navigation Links
Delayed in Biological Technology
FDA Approves KAPIDEX(TM) (Dexlansoprazole) delayed release capsules for the Treatment of GERD
... First proton pump inhibitor (PPI) with a Dual delayed Release(TM) (DDR) formulation DEERFIELD, ... (FDA) approved KAPIDEX(TM) (dexlansoprazole) delayed release capsules for the once-daily, oral ... the first proton pump inhibitor (PPI) with a Dual delayed Release(TM) (DDR) formulation designed to provide ...... The primary endpoint was delayed graft function defined as the need for dialysis ... to 12 months after transplantation, duration of delayed graft function, length of stay in hospital, ... perfusion significantly reduced the risk of delayed graft function compared to cold storage. 70 out ...
... of diabetic gastroparesis. Gastroparesis is a syndrome characterized by delayed emptying of the stomach into the intestine following a meal in the absence ... affecting approximately 8 million Americans. The syndrome refers to delayed gastric emptying, in the absence of mechanical obstruction of the stomach, ...
... had a median daily food intake of 1500 Kcal and 1600 Kcal in the acute and delayed period respectively, which is an adequate caloric consumption. ... The product has shown to be effective in preventing both acute and delayed CINV in patients receiving moderately emetogenic chemotherapies. A single ...
... post-ablation followed by a standard surgical lumpectomy. The early and delayed CEMRI findings were correlated with the surgical histopathology. In all 15 ... and/or small satellite lesions outside the cryoablation zone. At delayed CEMRI, previously unreported characteristic and reproducible findings of ...
... for intravenous administration since 2003 for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of ... receptor antagonist to be indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of ...
Protein Sciences Responds to Emergent BioSolutions Lawsuit
... meeting instead of forcing a vote on the transaction. Following the delayed shareholder meeting, PSC's board of directors re-affirmed that it remained ... to trying to complete a transaction with EBS. In a meeting following the delayed shareholder meeting, EBS now complained to PSC that the Proxy Statement ...Vion Reports 2008 First Quarter Results
... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...JCI table of contents: April 22, 2008
... affect the production of sex hormones and can cause either premature or delayed puberty as well as infertility. New data, generated in mice by Jacques ... under certain conditions, the formation of a thrombus in mice was delayed in the absence of CD36 and the thrombi that formed contained fewer ...Vion Pharmaceuticals Files Plan With Nasdaq
... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...... compared with Emend, with the potential to demonstrate better control over delayed chemotherapy-induced nausea and vomiting in patients taking highly ... Emend's 68 percent; however, more data is needed to confirm the effect on delayed chemotherapy-induced nausea and vomiting. Additionally, unless Rezonic ...
Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
... of California, San Diego ("UCSD") around the use of Cysteamine, and delayed Release Cysteamine ("DR Cysteamine") for the treatment of Non-alcoholic ... the Company's ability to initiate a Phase 2a study of Cysteamine or delayed Release Cysteamine in NASH patients in 2008, develop an oral formulation ...Vion Reports 2007 Fourth Quarter and Year-End Results
... approval for its products, particularly Cloretazine(R) (VNP40101M), delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...
Vion Pharmaceuticals to Implement a One-for-Ten Reverse Stock Split
... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...Vion Pharmaceuticals Holds Special Meeting of Stockholders
... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...Vion Pharmaceuticals Adds William Hahne, M.D. to Senior Management Team
... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty to ...... and other factors include risks that clinical trials for TPI 287 will be delayed due to institutional approvals, patient recruitment, formulation and ... and enforce our own intellectual property; that development of TPI 287 is delayed or terminated because the costs of further development exceed its value; ...
Vion Pharmaceuticals to Present at 20th Annual Bear Stearns Healthcare Conference
... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty ...... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty ...
Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
... Vion's potential inability to obtain regulatory approval for its products, delayed or unfavorable results of drug trials, the possibility that favorable ... accrual, or that any of these trials will not be discontinued, modified, delayed or ceased altogether. Except in special circumstances in which a duty ...KV Pharmaceutical Announces Stockholder Action to Amend By-Laws is Invalid
... as a result of so-called authorized-generic drugs; (7) new product development and launch, including the possibility that any product launch may be delayed or that product acceptance may be less than anticipated; (8) reliance on key strategic alliances; (9) the availability of raw materials and/or ...Telik Announces Second Quarter 2009 Financial Results
... to differ materially from those indicated by these forward-looking statements, including, among others, if clinical trials of TELINTRA or TELCYTA are delayed or unsuccessful, Telik's business would suffer, if Telik's competitors develop and market products that are more effective than its product ...Amicus Therapeutics Announces Second Quarter 2009 Financial Results
... the potential that it may be difficult to enroll patients in our clinical trials; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and, our dependence on third parties in the conduct of our clinical studies. ...... 6.8 million bone fractures annually in the United States. Of these fractures, it is reported that 5% to 10% do not heal properly due to non-union or delayed union of the bone due to the extreme severity of the fracture or because the patient is medically impaired due to an illness such as diabetes or ...
Sunesis Reports Financial Results for the Second Quarter 2009
... risks related to Sunesis' need for additional funding, the risk that Sunesis' drug development activities could be halted significantly or delayed for various reasons, the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval, the ...New Drug Application for Exenatide Once Weekly Accepted for Review by FDA
... clinical endpoints; label expansion requests or NDA filings not being submitted and/or accepted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA and/or exenatide once weekly may also be affected by government and ...... has troubling adverse events. BVA-601 induced a statistically significant reduction in the number of animals showing epileptic activity and delayed the onset of epileptic seizures. About Biovista's repositioning pipeline and technology platform Biovista applies high-efficiency ...
Wyeth Sets Webcast and Conference Call For 2009 Second Quarter Earnings
... call with research analysts at 8:00 a.m. Eastern Time on July 23, 2009. Interested investors and others may listen to the call live or on a delayed basis through our Internet webcast, which may be accessed by visiting our website at www.wyeth.com and clicking on the "Investor Relations" icon. ...... use of other drugs first. Prescribers should also consider the need to titrate Fanapt(TM) slowly to avoid orthostatic hypotension, which may lead to delayed effectiveness compared to some other drugs that do not require similar titration. IMPORTANT WARNINGS and PRECAUTIONS: increased mortality in ...
Microbix Sales Grow Over 30% In The Second Quarter; Up 43% In The First Half '09
... for Urokinase manufacturing, and the corresponding sales and marketing infrastructure. The anticipated launch of the drug Kinlytic has been delayed due to the ongoing review by the FDA of the Company's request for the release of this Urokinase product for distribution in the US market. The ...... siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam ...
Nektar Therapeutics Reports First Quarter 2009 Financial Results
... and efficacy findings; (ii) the timing or success of the commencement or end of clinical trials and commercial launch of partnered products may be delayed or unsuccessful due to slower than anticipated patient enrollment, drug manufacturing challenges, changing standards of care, clinical trial design, ...Exenatide Once Weekly New Drug Application Submitted to FDA for Type 2 Diabetes
... filings, including the NDA filing mentioned in this press release, not being submitted and/or accepted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA and/or exenatide once weekly may also be affected by government and ...... Foothill, LLC is the sole arranger, administrative agent and lender for both the term loan and revolving credit facility. This financing includes a delayed draw secured term loan facility of up to $10 million, and a secured revolving credit facility with a borrowing base derived from the value of certain ...
... siRNA drug in human clinical trials, developed by Quark for the prevention of acute kidney injury (AKI) following major cardiac surgery and of delayed graft function in kidney transplantation. For the structure of these products Quark has licenses from Silence Therapeutics and from Alnylam ...
China Sky One Medical, Inc. Provides Update on Filing Form 10-K
... whether these escrow shares will lead the company to record a non-cash compensation expense during 2008. This is the only outstanding issue that has delayed the filing of its annual report on form 10-K. On a pro forma basis that excludes the impact of any potential non-cash, non-operational expense ...Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
... Application ("NDA") filings, including the NDA filing for exenatide once weekly, not being submitted in a timely manner; regulatory approval being delayed or not received; or manufacturing and supply issues. The potential for BYETTA, SYMLIN and/or exenatide once weekly may also be affected by government ...Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2008 Financial Results
... funding; the risk that Sunesis' development activities for voreloxin, including enrollment and reporting of results, could be halted significantly or delayed for various reasons; the risk that Sunesis' clinical trials for voreloxin may not demonstrate safety or efficacy or lead to regulatory approval; the ...Other ContentsdepressiondepressiondepressiondepressiondepressiondepressiondepressioninbreedinginbreedingincisorincisordominancedominancedominancedominancedominanceincompleteincompleteincompleteincompleteincompleteincompleteincompleteassortmentassortmentassortmentassortmentassortmentindependentindependentindependentindependentindependentindependentindependentindependentindependentOther TagsLithoEMAEMAEMAEMAEMAEMAEMACSTCSTCystoscopeOther Tagscongestion 2electronics 2cost 2cost 3cost 4cost 5cost 6cost 7cost 8cost 9cost 10increase 2increase 3increase 4increase 5increase 6increase 7increase 8increase 9increase 10boosting 2insect 2insect 3insect 4insect 5insect 6insect 7applications 2applications 3applications 4applications 5applications 6applications 7applications 8applications 9applications 10pharmaceutical 2pharmaceutical 3pharmaceutical 4pharmaceutical 5pharmaceutical 6pharmaceutical 7pharmaceutical 8
(Date:11/24/2009)...et science is opening new doors to understanding h...the hearing of a marine mammal or if they hear it...ed X-ray scanners that NASA uses to detect flaws i...is now allowing scientists to peek inside the gian...d three-dimensional replicas of a whale,s hearing ...
(Date:11/24/2009)...atomic-level action of a remarkable class of ring-...chers with the Lawrence Berkeley National Laborato... crystallography beamline at the Advanced Light So...s in gene expression and replication, and are vita... as infectious agents, such as the human papilloma...
(Date:11/24/2009)...TON ROUGE Antarctica has long held secrets of the...il recently, there has been very little informatio...h miles of ice for millions of years. Now, a team ...SU have been funded to the tune of $10 million do...to get to the bottom of things literally. These s...
Breaking Biology News(10 mins):Rocket science leads to new whale discovery 2Atomic-level snapshot catches protein motor in action 2Atomic-level snapshot catches protein motor in action 3Atomic-level snapshot catches protein motor in action 4LSU gets to the bottom of things -- in Antarctica 2Covidien receives FDA clearance for its Puritan Bennett 840 ventilator system 53868 1Covidien receives FDA clearance for its Puritan Bennett 840 ventilator system 53868 2Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 1Carnegie Mellons Jean VanBriesen leads research team on Monongahela River 9506 2Wastewater produces electricity and desalinates water 9504 1Wastewater produces electricity and desalinates water 9504 2Wastewater produces electricity and desalinates water 9504 3(Date:11/27/2009)...s to bring unprecedented medical, economic burdens...althDay News) -- The number of people with diabete...the next 25 years, a new study predicts. , That...on people with the disease, up from 23.7 million t... people with diabetes will triple, the study also ...
(Date:11/27/2009)... Voyant Health™ announced today... licensed its TraumaCad Enterprise orthopedic temp...solution. , (PRWEB) Novem...ay that Spectrum Health (Grand Rapids, Michigan) h...mplating solution and its TraumaCad Extend workflo...
(Date:11/27/2009)... Specialist manufacturers who use med... saving millions of dollars by bringing in technol...ncreasing numbers of pro-active medical manufactur...e concept stage of their projects, ensuring that p... processes or potentially outdated technology. , ...
(Date:11/26/2009)...ORK,Nov.27/PRNewswire/--Withcoldandfluseasonuponus...ontrolthespreadofinfectionsandavoidillness. ,, ...buttoavoidtransmittingillnessifwe,resick,"saidEile...nursingdirectorforinfectioncontrolandoccupationalh...,, HospitalforSpecialSurgeryhasoneofthelowestin...
(Date:11/26/2009)...t 25 years, the number of Americans living with di...llion in 2009 to 44.1 million in 2034. Over the sa..., rising from $113 billion to $336 billion, even w...archers based at the University of Chicago report ...number of those with diabetes covered by Medicare ...
Breaking Medicine News(10 mins):Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3[0] Diabetes Cases Expected to Double in 25 Years[0] Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend[0] Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells[1] Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use[0] Diabetes cases to double and costs to triple by 2034
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |